⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11269673 | 1.00 | — | — | |
| SCHEMBL16653312 | 0.78 | — | — | |
| SCHEMBL13486733 | 0.76 | — | — | |
| SCHEMBL775207 | 0.60 | — | — | |
| SCHEMBL4574517 | 0.60 | HDAC4 (0.32) | — | |
| SCHEMBL31591216 | 0.58 | — | — | |
| SCHEMBL2083274 | 0.57 | — | — | |
| SCHEMBL17147691 | 0.56 | — | — | |
| SCHEMBL1192447 | 0.56 | — | — | |
| SCHEMBL31341750 | 0.56 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4573089-A2 | KRAS INHIBITORS | Bristol-Myers Squibb Company (US) | 2025-06-25 | — | — | EP | disclosed |
| CN-119998275-A | KRAS inhibitors | 百时美施贵宝公司 | 2025-05-13 | — | — | CN | disclosed |
| WO-2024220543-A1 | NK3 MODULATORS AND USES THEREOF | KALLYOPE, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| US-20240199584-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-06-20 | — | — | US | disclosed |
| WO-2024040109-A2 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-02-22 | — | — | WO | disclosed |
| US-4321383-A | Heterobicyclo intermediates | E. R. SQUIBB & SONS, INC. (US) | 1982-03-23 | — | — | US | disclosed |
| US-4303662-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1981-12-01 | — | — | US | disclosed |